Léger Serge, Bayly Christopher I, Black W Cameron, Desmarais Sylvie, Falgueyret Jean-Pierre, Massé Frédéric, Percival M David, Truchon Jean-François
Merck Frosst Centre for Therapeutic Research, PO Box 1005, Pointe-Claire-Dorval, Que., Canada H9R 4P8.
Bioorg Med Chem Lett. 2007 Aug 1;17(15):4328-32. doi: 10.1016/j.bmcl.2007.05.024. Epub 2007 May 16.
The nitrile warhead used in a series of cathepsin K inhibitors can be replaced by a less electrophilic primary amide. The accompanying loss of potency can be partially recovered by introducing a substituent alpha to the amide. The potency gain resulting from this addition is not achieved with the nitrile derivatives due to a different geometry of the cysteine adduct in the enzyme active site. This study led to the identification of the primary amide 2g, which is an inhibitory substrate, with an IC(50) of 10 nM against cathepsin K and excellent selectivity versus the other cathepsins.
一系列组织蛋白酶K抑制剂中使用的腈弹头可被亲电性较弱的伯酰胺取代。通过在酰胺的α位引入取代基,可部分恢复随之而来的活性损失。由于酶活性位点中半胱氨酸加合物的几何结构不同,腈衍生物无法实现这种添加所带来的活性增强。这项研究导致了伯酰胺2g的鉴定,它是一种抑制性底物,对组织蛋白酶K的IC(50)为10 nM,对其他组织蛋白酶具有优异的选择性。